Antibody-Drug Conjugates in EGFR-Mutant NSCLC

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

Related Keywords

,Evolving Treatment Paradigm ,Advanced Non ,Small Cell Lung Cancer ,Drug Conjugates ,Non Small Cell Lung Cancer ,Nsclc ,Advanced Non Small Cell Lung Cancer ,Advanced Nsclc ,Nsclc Treatment ,Egfr Mutant Lung Cancer ,Egfr Mutated Lung Cancer ,Second Line Treatment ,Herthena Lung01 ,Tropion Lung05 ,Patritumab Deruxtecan ,Datopotamab Deruxtecan ,